Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 503 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control vision therapy Clear all
Completed Not applicable Interventional

Overcoming Barriers in Vision Care Utilization of African Americans With Diabetes

NCT01744132
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetes Mellitus
Interventions
Aim 3: Contract
Behavioral
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 30, 2026, 11:42 AM EDT
Completed Phase 3 Interventional

A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis

NCT00404742
View directory record Official record
Conditions
Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
Interventions
Placebo, LX211
Drug
Lead sponsor
Lux Biosciences, Inc.
Industry
Eligibility
13 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chicago, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Oct 30, 2026, 11:42 AM EDT
Terminated Not applicable Interventional Results available

Use of a Loading Dose of Vancomycin in Pediatric Dosing

NCT01290237
View directory record Official record
Conditions
Infection
Interventions
vancomycin hydrocloride
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 18 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 30, 2026, 11:42 AM EDT
Withdrawn Not applicable Interventional

Pilot Study of the Effects of Circadian Rhythms on the Treatment of Bipolar I Depression.

NCT00726154
View directory record Official record
Conditions
Bipolar Disorder
Interventions
IPSRT, Collaborative Care
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Oct 30, 2026, 11:42 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia

NCT05124275
View directory record Official record
Conditions
Presbyopia
Interventions
Pilocarpine Ophthalmic Topical Cream, Dose 1, Pilocarpine Ophthalmic Topical Cream, Dose 2, Pilocarpine Ophthalmic Topical Cream, Dose 3, Placebo Ophthalmic Topical Cream
Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
40 Years to 55 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
10
States / cities
Chandler, Arizona • Sun City, Arizona • Glendale, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 30, 2026, 11:42 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease

NCT04181593
View directory record Official record
Conditions
Dry Eye
Interventions
Omega 3 fatty acid, Placebos
Drug
Lead sponsor
OmegaD LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Newport Beach, California • Westminster, California • Largo, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 30, 2026, 11:42 AM EDT
Not listed Not applicable Interventional

United States Coronary Artery Bypass Surgery (CABG) Diabetes Project (USCDP) Pilot Study

NCT00646438
View directory record Official record
Conditions
Diabetes, Coronary Artery Disease
Interventions
Strict Glycemic Control for one year post-op CABG
Drug
Lead sponsor
Providence Heart & Vascular Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 4, 2009 · Synced Oct 30, 2026, 11:42 AM EDT
Completed Not applicable Interventional Results available

Behavioral and Enhanced Perinatal Intervention for Cessation (B-EPIC): Reducing Tobacco Use Among Opioid Addicted Women

NCT03796208
View directory record Official record
Conditions
Smoking Cessation
Interventions
Behavioral and Enhanced Perinatal Intervention for Cessation (B-EPIC), Treatment As Usual
Behavioral
Lead sponsor
Kristin Ashford
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 15, 2022 · Synced Oct 30, 2026, 11:42 AM EDT
Active, not recruiting Not applicable Interventional

A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy

NCT05316584
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions
Remote monitoring
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 30, 2026, 11:42 AM EDT
Completed Phase 3 Interventional

A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract

NCT04539548
View directory record Official record
Conditions
Cataract
Interventions
Dextenza Ophthalmic Insert, Prednisolone acetate ophthalmic suspension USP 1%
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
0 Years to 5 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
14
States / cities
Aurora, Colorado • Fort Collins, Colorado • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Oct 30, 2026, 11:42 AM EDT
Completed Not applicable Interventional Results available

Luminopia One Amblyopia Vision Improvement Study

NCT03608150
View directory record Official record
Conditions
Amblyopia
Interventions
Luminopia One, Refractive Correction
Device
Lead sponsor
Luminopia
Industry
Eligibility
4 Years to 7 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
22
States / cities
Los Angeles, California • Gainesville, Florida • Maitland, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 30, 2026, 11:42 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

RCT for Latina Mental Health Using Web-Based Apps

NCT06874790
View directory record Official record
Conditions
Mental Health, Anxiety, Depression, Well-Being, Psychological
Interventions
Catalina, Control webpage
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Female only
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 30, 2026, 11:42 AM EDT
Completed Phase 1Phase 2 Interventional

Sirolimus in Treating Patients With Glioblastoma Multiforme

NCT00047073
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
Rapamycin, Surgery, Supportive Care
Drug · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 30, 2026, 11:42 AM EDT
Completed Phase 2 Interventional Results available

RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms

NCT05595369
View directory record Official record
Conditions
Long COVID, Long Covid19
Interventions
Experimental: Paxlovid 25 day dosing, Experimental: Paxlovid 15 day dosing, Placebo Comparator: Control
Drug
Lead sponsor
Kanecia Obie Zimmerman
Other
Eligibility
18 Years and older
Enrollment
963 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 30, 2026, 11:42 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.

NCT04049266
View directory record Official record
Conditions
Wet Macular Degeneration
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
50 Years and older
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
59
States / cities
Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 53 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Oct 30, 2026, 11:42 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies

NCT04622345
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
VSJ-110, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 30, 2026, 11:42 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Effect of Rinsing on Ocular Inflammation and Symptoms in Patients With Dry Eye Disease

NCT07618364
View directory record Official record
Conditions
Dry Eye Syndromes, Dry Eye, Ocular Surface Disease
Interventions
Rinsada
Device
Lead sponsor
Rinsada
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 30, 2026, 11:42 AM EDT
Not listed Not applicable Interventional

Priming Motor Learning Through Exercise in People With Spinocerebellar Ataxia

NCT05826171
View directory record Official record
Conditions
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 7
Interventions
High-Intensity Aerobic Exercise Prior to Balance Training, Low-Intensity Exercise Prior to Balance Training
Behavioral
Lead sponsor
Teachers College, Columbia University
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 30, 2026, 11:42 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Ovarian PRP Injections for Improved Embryo Quality Using Embryo Quality Score

NCT07020546
View directory record Official record
Conditions
Infertility, Poor Ovarian Reserve, Embryo Growth Disorder, in Vitro Fertilization
Interventions
Ovarian Platelet-rich plasma (PRP) injections
Procedure
Lead sponsor
Generation Next Fertility
Other
Eligibility
18 Years to 47 Years · Female only
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 30, 2026, 11:42 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Understanding Needs of Older Patients Prior to Starting Cancer Treatment

NCT07225920
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Survey Administration, Interview, Educational Intervention, Assessment, Internet-Based Intervention, Electronic Health Record Review
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
39
States / cities
Tuscaloosa, Alabama • Fort Smith, Arkansas • Jonesboro, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 30, 2026, 11:42 AM EDT
Completed Phase 2 Interventional

Iontophoretic Delivery of EGP-437 in Patients Who Have Undergone Cataract Surgery

NCT03180255
View directory record Official record
Conditions
Cataract, Anterior Chamber Inflammation, Pain, Postoperative
Interventions
Dexamethasone phosphate, Placebo
Combination Product · Other
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Oct 30, 2026, 11:42 AM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Clinical Decision Support for Safety of Opioid Transitions

NCT06527040
View directory record Official record
Conditions
Medication Abuse, Harm Reduction
Interventions
Opioid Transitions Clinical Decision Support (CDS)
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 89 Years
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 30, 2026, 11:42 AM EDT
Completed Phase 4 Interventional Results available

Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

NCT04505774
View directory record Official record
Conditions
Covid19
Interventions
theraputic heparin, prophylactic heparin, P2Y12, Crizanlizumab Injection, SGLT2 inhibitor
Drug
Lead sponsor
Matthew Neal MD
Other
Eligibility
18 Years and older
Enrollment
3,591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
81
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Oct 30, 2026, 11:42 AM EDT
Completed Phase 2 Interventional

Next Generation Rocklatan

NCT06441643
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
AR-17043 Ophthalmic Solution, PG043 Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution, Netarsudil 0.02% Ophthalmic Solution, Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution, AR-17043 Vehicle
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
Garden Grove, California • Inglewood, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 30, 2026, 11:42 AM EDT